Every material Form 8-K ONCOLYTICS BIOTECH INC has filed with the SEC since October 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oncolytics Biotech announced translational data from a Phase 1b/2 trial in relapsed/refractory multiple myeloma patients, showing that pelareorep can engage the immune system and combine with standard-of-care therapies. The data will be presented as a poster at the 68th American Society of Hematology Annual Meeting and Exposition, and the filing includes no financial results, guidance, or new trial efficacy figures.
Poster presentation (Abstract 2183) scheduled for Saturday, December 12, 2026 at the ASH Annual Meeting
Phase 1b/2 trial compared bortezomib, dexamethasone and pembrolizumab (Cohort 1) with pelareorep plus those drugs (Cohort 2)
Patients had a median of four prior lines of therapy, with a range of three to eleven
Patients who responded to treatment showed greater expansion of CD8 effector memory T cells than non-responders
Oncolytics Biotech reported translational data from a Phase 1/2 study in second-line or later squamous cell anal cancer patients, presented at the SITC 2026 Annual Meeting. The company said pelareorep combined with a checkpoint inhibitor more than doubled the objective response rate and increased median duration of response by 50% versus the current approved therapy in that population, though the immune data rest on small patient numbers.
Seven of eight evaluable patients showed greater than two-fold increases in immune-activation biomarkers after one cycle of therapy
Six of 14 patients evaluated for HPV-16 immune responses showed HPV-16 clonal expansion, and four of those had tumor shrinkage
The company cited a potential $3 to 5 billion market for HPV-associated cancers, based on its internal estimates
Oncolytics Biotech reported updated Cohort 4 data from its Phase 1/2 GOBLET study of pelareorep with atezolizumab in second-line and later squamous cell anal cancer. The company says the median duration of response is about 15 months, compared with 9.5 months for an FDA-approved retifanlimab monotherapy in a similar population, but the filing offers no revenue, earnings, or financing figures and the results remain early clinical data.
Median duration of response is approximately 15 months; median overall survival has not yet been reached
All patients who responded to treatment survived beyond 12 months, according to the company
The filing says the 15-month estimate comes from the company's internal calculations for this draft
Company cites FDA Fast Track Designation and recent FDA interactions as support for registrational development
Oncolytics Biotech said it will present a trial-in-progress abstract and e-poster on its randomized REO 033 study of pelareorep in second-line RAS-mutant, MSS metastatic colorectal cancer at the European Society for Medical Oncology Congress 2026. The company said recent FDA interactions opened the option of a pivotal expansion (Part B) that could support an accelerated approval submission based on objective response rate and a full approval based on progression-free survival.
The e-poster is presentation number 994eTiP, and the study will randomize 30 patients per arm.
The primary endpoint is objective response rate; secondary endpoints include overall survival and progression-free survival.
The filing says a possible Part B expansion could support accelerated approval based on ORR and full approval based on PFS, but no Part B has been initiated as stated in the filing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ONCOLYTICS BIOTECH INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →